首页> 外文期刊>The Lancet infectious diseases >Rotavirus vaccination in Europe: Drivers and barriers
【24h】

Rotavirus vaccination in Europe: Drivers and barriers

机译:欧洲轮状病毒疫苗接种:驱动因素和障碍

获取原文
获取原文并翻译 | 示例
           

摘要

Rotavirus gastroenteritis is a vaccine-preventable disease that confers a high medical and economic burden in more developed countries and can be fatal in less developed countries. Two vaccines with high efficacy and good safety profiles were approved and made available in Europe in 2006. We present an overview of the status of rotavirus vaccination in Europe. We discuss the drivers (including high effectiveness and effect of universal rotavirus vaccination) and barriers (including low awareness of disease burden, perception of unfavourable cost-effectiveness, and potential safety concerns) to the implementation of universal rotavirus vaccination in Europe. By February, 2014, national universal rotavirus vaccination had been implemented in Belgium, Luxembourg, Austria, Finland, Greece, Luxembourg, Norway, and the UK. Four other German states have issued recommendations and reimbursement is provided by sickness funds. Other countries were at various stages of recommending or implementing universal rotavirus vaccination.
机译:轮状病毒肠胃炎是一种疫苗可预防的疾病,在发达国家中给医疗和经济带来沉重负担,而在欠发达国家中可能致命。 2006年,在欧洲批准并提供了两种具有高功效和良好安全性的疫苗。我们概述了欧洲轮状病毒疫苗的接种状况。我们讨论了在欧洲实施通用轮状病毒疫苗的驱动因素(包括通用轮状病毒疫苗的高效性和效果)和障碍(包括对疾病负担的认识不足,对不利的成本效益的认识以及潜在的安全隐患)。到2014年2月,已在比利时,卢森堡,奥地利,芬兰,希腊,卢森堡,挪威和英国实施了全国通用轮状病毒疫苗接种。德国的其他四个州也已发布建议,疾病基金提供了报销。其他国家处于建议或实施通用轮状病毒疫苗接种的各个阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号